Dr. Miller has over 20 years of experience developing and launching products in the life science and high technology industries. He previously held the position of Chief Operating Officer at ProterixBio and was General Manager of the Boston site.
Prior to ProterixBio, he held the position of VP of Product Development and Operations as BioScale. He had joined BioScale soon after its founding and led product development for the company’s first product, an automated immunoassay platform utilizing a unique non-optical detection method based on MEMS technology. As VP of Product Development, he managed a multi-disciplinary team of scientists and engineers covering instrumentation, software, consumables and assay development. He led the transition of the product into manufacturing and subsequently took on additional operations responsibilities, including field support, manufacturing and facilities.
Prior to BioScale, Dr. Miller held several product development leadership positions at Axsun Technologies, a company producing optical subsystems for telecommunications and medical device markets. His responsibilities spanned the phases of early prototype development, system qualification, and manufacturing scale-up.
Prior to Axsun, he was a Principal Engineer at Physical Sciences Inc., where he worked on instrumentation and control devices for aerospace applications. While at PSI, he initiated a new business area focused on MEMS technology, winning multiple research grants to support the development of multiple novel devices.
Dr. Miller earned a B.S. in Mechanical Engineering from the Rensselaer Polytechnic Institute, and an M.S. and Ph.D. in Mechanical Engineering from Stanford University. He is inventor or co-inventor on over 25 issued patents with an additional 20 pending patent applications.
Prior to joining ProterixBio, Brett Masters served as VP of Engineering at Midé Technology Corporation. Dr. Masters joined Midé in early 1997 and the role of VP of Engineering in 1998.
Dr. Masters’ educational background includes a Doctor of Science, a Master of Science, and a Bachelor of Science in Aeronautics and Astronautics from the Massachusetts Institute of Technology. Prior to this, Dr. Masters attended the University of Auckland in his homeland of New Zealand.
Dr. Masters has received several awards including the NASA OAST “Commendation for Technology Excellence” for the Middeck 0-Gravity Dynamics Experiment as well as the 1994 ASME Structures and Materials Award for work presented on “Global Structure Modeling Using Force-State Component Identification”. He also won the James Mean Memorial Award (MIT) for outstanding contribution in the design of a high-flying aircraft for sampling of ozone in the Antarctic Circle as well as the Luis de Florez Award (MIT) for design ingenuity in developing, building and testing a v-shaped hydrofoil for windsurfing.
Dr. Colón brings over 25 years experience in biopharma, genomics, diagnostics, health care, drug delivery and industrial biotechnology.
In addition to her role at ProterixBio, she is President and CEO at InCarda Therapeutics, a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. She is also a senior advisor at New Science Ventures (where she was formerly a partner) and serves on the boards of Paradigm Diagnostics, PerceptiMed and Cocoon Biotech, and is an advisor at Kiverdi. She is also a member of the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University.
Previously, she was founding President of the Industrial Products Division and Senior Vice President at Intrexon Corporation (NYSE:XON) where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals and was a key contributor to the company’s $100M Series E raise.
Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences (Nasdaq:GILD), where she was responsible for global execution of clinical trials. At Gilead, she also created and led both the Alliance Management and Commercial Strategic Planning groups.
Prior to Gilead, she was VP, Corporate Planning at Affymetrix (acquired by ThermoFisher), where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics.
Earlier in her career, Grace was a consultant at McKinsey & Company, where she served clients in healthcare, high tech, consumer goods and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow and recipient of multiple NIH training grants. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
Martin Latterich, PhD, currently serves as the Chief Scientific Officer of ProterixBio. Dr. Latterich brings nearly 20 years of academic, commercial and technology development experience to ProterixBio and features an accomplished research career focused on the proteomics-based discovery of novel biomarkers in oncology, respiratory disease and neurodegenerative disorders. Most recently Martin served as a Professor at the Proteogenomics Research Institute for Systems Medicine in San Diego, where his laboratory used proteomics and genomics to discover novel biomarkers of cancer and degenerative disease though a systems biology approach that includes proteomics. He was also the CSO, co-founder and a board member for the non-profit Nicholas Conor Institute for Pediatric Cancer Research. Martin’s work at the institute included designing new technologies to enable the better treatment of children with cancer, using personalized medicine technology to match their unique genetic make-up and tumor physiology to available treatment options. He previously served on the faculty of the University of Montreal, McGill University and the Salk Institute. His grant-funded work has been recognized by the 2003 Tier I Canada Research Chair, the 1998 Pew Scholar Award and the 1997 Basil O’Connor Starter Scholar Award.
Dr. Latterich also held senior management positions at several biotechnology companies, including Diversa and Illumina, where he headed their proteomics initiatives. He has made significant contributions to the field of cell biology, clinical biomarker discovery, proteomics and genomics. Among his recent discoveries are biomarkers for cancer, respiratory disease and neurodegenerative disorders. Dr Latterich has edited a book on RNAi, is author on over 32 publications in leading scientific journals and is listed on numerous patent applications. Martin is Editor-in-Chief of the scientific journal Proteome Science. He has served on several national and international study sections. He was a postdoctoral fellow in the laboratory of the 2013 Nobel Laureate Dr. Randy Schekman at the HHMI and University of California, Berkeley. Dr. Latterich earned his Ph.D. in cell biology and a B.Sc. in biochemistry and molecular biology from Durham University, U.K.